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Summary
Cyclin-dependent kinase 5 (Cdk5) is widely viewed as
a possible target for a wide variety of neurological
disorders. One pathological role attributed to Cdk5 is
the abnormal phosphorylation of tau that may lead
to the neuronal inclusions known as neurofibrillary
tangles. A high through-put screen for inhibitors of
Cdk5-mediated phosphorylation of tau resulted in
three compounds with distinct mechanisms of action.
One compound is competitive with ATP and has a
high affinity for the Cdk5 ATP binding pocket. The
second compound also competes with ATP, is non-
competitive with tau, and (uniquely among this class
of inhibitors) displaces adjacent amino acid residues
to make room for the nitrophenyl group. A third com-
pound did not compete with ATP, but did compete
with tau at low concentrations of tau. The SAR and
charge optimization derived from cocrystals of the
two ATP competitors along with cocrystals of three
other ATP competitors map out the importance of fill-
ing and properly charging different regions of the ATP
binding pocket. Taken together, this analysis shows
how the structure of Cdk5 constrains the space of
potential inhibitors and reveals a pocket unfilled in all*Correspondence: kosik@lifesci.ucsb.edu
5 Present address: Department of Pathology, College of Physicians
and Surgeons, Columbia University, New York, New York 10032.
6 Present address: Eli Lilly & Company, Lilly Corporate Center, Indi-
anapolis, Indiana 46285.
7 Present address: Neuroscience Research Institute, University of
California, Santa Barbara, Santa Barbara, California 93106.of the structures. These leads could be a starting
point for structure-based drug design of more potent
and selective inhibitors.
Introduction
Cdk5 is a member of a family of proline-directed serine/
threonine kinases that is primarily active in the nervous
system [1] and is essential for the development of the
nervous system [2]. This kinase has 60% homology to
human Cdk2 and cell division cycle kinase 2 (CDK1)
[3–5]. In contrast to other members of the cyclin-
dependent kinase family, Cdk5 does not mediate pro-
gression through the cell cycle. Rather, its activity is
found predominantly in postmitotic neurons [6]. Al-
though Cdk5 is expressed in many tissues, the basis
for its localized activity is the restricted expression of
the activators p35 and p39 [7]. A large body of data
supports a role for this kinase in the pathogenesis of
Alzheimer’s disease (AD), amyotrophic lateral sclerosis
(ALS), Parkinson’s disease, Niemann-Pick type C dis-
ease, and ischemia [8–12]. However, controversy still
exists as to the exact role of Cdk5 in these diseases
[13].
The multiple disease phenotypes to which Cdk5 is
thought to contribute are based on the large number of
Cdk5 substrates. For example, phosphorylation of the
NR2A subunit of the NMDA receptor by Cdk5 was
shown to be responsible for hippocampal CA1 cell
death after transient forebrain ischemia [12]. As a tau
kinase [14, 15], Cdk5 has been implicated in the patho-
genesis of the Alzheimer neurofibrillary tangles (NFTs)
[16, 17], which are composed mainly of hyperphosphor-
ylated tau aggregates. Strong support for assigning a
role to Cdk5 comes from studies in transgenic mice [18,
19]. An attractive proposed mechanism for increased
Cdk5 activity is an excessive upregulation of the Cdk5
activators following their truncation and release of the
active complex from a membranous compartment [20].
The activators, p25 and p29, are proteolytic products
containing the C-terminal portion of p35 and p39, re-
spectively. p25, produced by calpain cleavage of p35
between residues 98 and 99 upon neurotoxic insults
[21, 22], is fully capable of activating Cdk5. In addition,
p25 is more stable than p35 and dissociates from its
membrane attachment site to the cytosol [20].
The crystal structure of the Cdk5/p25 complex has
clarified the mechanism of Cdk5 activation by p25 [23].
In general, Cdk activation requires a dual mechanism:
binding of the cyclin box fold (CBF) region of the cyclins
and the phosphorylation of Thr160 or Thr161 in the acti-
vation loop (also known as T-loop) by the Cdk-activa-
ting kinase [24]. In contrast, the Cdk5 activator, p25,
contains a highly divergent CBF domain, which elicits
an active conformation of CDK5 in the absence of
phosphorylation [23]. Essentially, p25 tethers the T-loop
of CDK5 into its active position.
Several classes of chemical inhibitors for Cdk have
been reviewed [25]. Generally, these small molecules
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812compete with ATP and have IC50 values in the micromo- C
nlar range [26–33]. Hymenialdisine inhibits in vivo phos-
phorylation of tau at AD-specific sites in cultured insect s
scells [34]. Alsterpaullone, a selective inhibitor for Cdk5
and GSK (glycogen synthetase kinase), inhibits the in
ivivo phosphorylation of tau at AD-specific sites in an
insect cell line model and DARRP-32 phosphorylation o
sin mouse striatum slices [31]. Some of the inhibitors
have been cocrystalized with Cdk2 [35–37]. Recently, u
1data on the crystal structure of active Cdk5/p25 kinase
complexed with three inhibitor moieties, (R)-roscovi- a
Ttine, aloisine-A [32], and indirubin-3#-oxime [38], have
been reported [39]. These chemical species inhibit ca- t
ctalytic activity by binding to the conserved ATP bind-
ing pocket.
pHere we report the discovery of three small molecule
Cdk5 inhibitors. Each of them has a distinct mechanism t
lof action. Together they suggest novel opportunities for
the design of compounds that could selectively inhibit c
uCdk5.
b
tResults
r
LIdentification of Cdk5 Inhibitors
aand Their Inhibitor Kinetics
hWe previously configured a high-throughput assay to
dscreen for inhibitors of tau phosphorylation at sites 396
sand 404 mediated by Cdk5 [40]. A low concentration of
sfull-length recombinant tau (0.1 M) and a high concen-
(tration of ATP (200 M) were used for the screen. The
tdegree of tau phosphorylation was determined using
PHF-1 antibody, which recognizes phosphorylation at
serine 396 and serine 404. By performing the screen at I
Tthe relatively high ATP concentration of 200 M, inhibi-
tors with a variety of kinetic properties emerged. w
rVarious computational filters were applied to select
compounds for the chemical library with an increased c
wprobability of oral bioavailability and blood brain barrier
(BBB) penetration, which includes calculations of polar a
asurface area (a physico-chemical descriptor that strongly
correlates with oral bioavailability and the ability to a
ocross the BBB), Lipinski’s “rule of five,” and other desir-
ability filters. All compounds in the collection were m
eplated in 384-well plates. Approximately 58,000 com-
pounds were screened. This portion of the compound T
glibrary consists of compounds purchased from eight
primary vendors: Maybridge (9,000), Peakdale (3,000), t
iBionet (5,000), CEREP (4,800), ChemDiv (30,000), Prest-
wick collection of FDA-approved drugs (640), a natural a
iproduct collection from Specs (480), and a tetrapeptide
collection from Advanced Syntech (4,100), as well as s
850 compounds from various academic labs and 595
unique compounds synthesized in-house. The hit rate 1
2after confirmation was 0.5% and the top three, based
on their structure and IC50, represent three major a
hclasses: a xanthen-9-one natural product bellidin, com-
pound 1.0, a 4-aminothiazole, compound 2.0, and a
12,3-dihydro-1H-4-oxa-2,5-diazaphenanthrenes, com-
pound 3.0 (Figure 1). w
(1.0 had an IC50 of 0.2 M and is a competitive inhibi-
tor for ATP binding. Kinetic studies indicated that 1.0 o
ihas a Ki of w0.17 M under a saturated concentration
of tau (20 M) (Figure 1D). It was reported [41] that pdk5 acts by a random, anticooperative kinetic mecha-
ism. Under such a mechanism, binding of one sub-
trate greatly decreases the affinity for the binding of a
econd substrate.
2.0 showed competitive inhibition against ATP bind-
ng with a Ki of 0.6 M under a saturated concentration
f tau (20 M) (Figure 1E). The compound also demon-
trated noncompetitive inhibition against tau binding
nder saturating ATP concentration (400 M) (Figure
F). Thus, binding of 2.0 to the ATP pocket appears to
ffect the enzyme binding to a second substrate, tau.
he differences in kinetic modes of these two competi-
ive inhibitors to the ATP site may be reflected in their
ocrystal structures (see below).
3.0 did not compete with ATP for binding to Cdk5/
25 (data not shown). 3.0 did not inhibit phosphoryla-
ion by Cdk5 when tau was used at its Km (w4 M). At
ow concentrations of tau (up to 0.6 M), 3.0 bound
ompetitively with tau with an apparent Ki of 8 M (Fig-
re 1G) according to a Dixon plot (Figure 1H). The inhi-
ition of 3.0 was abolished at high concentrations of
au. When histone H1 (Km = 80 M) and a peptide de-
ived from histone H1 (Pro-Lys-Thr-Pro-Lys-Lys-Ala-
ys-Lys-Leu) (Km = 600 M) were used as substrates
t the same low concentrations as tau, 3.0 did not in-
ibit the phosphorylation of histone H1 and a peptide
erived from histone H1 (data not shown). The greater
pecificity of 3.0 for tau as a Cdk5 substrate was also
uggested by comparing the IC50s values of 3.0 for tau
17.0 M) to FAK (271.8 M), another well-charac-
erized Cdk5 substrate [42].
nhibitory Effects in Cells, Toxicity, and Specificity
he effects of the compounds on tau phosphorylation
ere studied in the neuroblastoma cell line IMR-32 and
at primary neurons. IMR-32 has been shown to contain
onstitutively active Cdk5 [43]. Cells were incubated
ith the compounds for 2 hr, lysed, and sequentially
nalyzed by immunoblot, first with monoclonal PHF-1
ntibody, and then with a second polyclonal antibody
gainst total tau (Figure 2A). At 2 hr no toxicity was
bserved. Total tau was used as a control. 1.0 had a
inimal effect on tau phosphorylation in both cell types
ven at 50 M, presumably due to low cell permeability.
his compound is quite hydrophilic with four hydroxyl
roups, which may contribute to the low penetration
hrough the cell membrane. 2.0 had a dose-dependent
nhibition on tau phosphorylation in both IMR-32 cells
nd primary neurons with an EC50 < 20 M. 3.0 inhib-
ted Cdk5/p25 phosphorylation of tau at the PHF-1
ites with an EC50 < 50 M.
Cell viability was assayed in HT1080 cells (Figure 2B).
.0 had no apparent cytotoxicity up to 100 M at either
4 or 48 hr incubation. 2.0 had an LD50 of 33 M at 24
nd 48 hr incubation. 3.0 had an LD50 of 13 M for 24
r and 7 M for 48 hr incubation.
Glycogen synthetase kinase 3β, CDK1, casein kinase
, protein kinase A, protein kinase C, and Src kinase
ere tested with these three inhibitors for specificity
see Supplemental Table S1 available with this article
nline). 1.0 inhibited Cdk5 and CDK1 equally; however,
t has a higher IC50 toward GSK3β and casein kinase,
rotein kinase C, and Src kinase. 2.0 is a better inhibitor
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813Figure 1. Chemical Structures, SAR, and Ki-
netics
(A–C) Chemical structures of Cdk5/p25 in-
hibitors and structure activity relationships.
3.0 and 3.1 have similar inhibitory properties;
however, 3.1 is more soluble. The asterisk in-
dicates that the value for 3.2 is not a true
IC50 value due to its limited solubility. By
curve fitting, we concluded that 50% inhibi-
tion was achieved at 2.3 M.
(D and E) Compounds 1.0 and 2.0 are ATP
competitive inhibitors.
(F) Compound 2.0 is also noncompetitive
with tau. The degree of phosphorylation by
Cdk5 was evaluated by the filter method, as
described in Experimental Procedures. Vari-
ous concentrations of ATP (0–400 M) for
the ATP competition or tau (0–40 M) for the
tau competition were incubated with Cdk5/
p25 in the absence (square) or IC50 (up trian-
gle) or IC80 (down triangle) concentration of
inhibitors for 60 min at 30°C. Each point rep-
resents mean ± SEM. A graph of the double-
reciprocal of the degree of phosphorylation
against substrate (ATP or Tau) concentration
is plotted.
(G) The inhibition of Cdk5 activity by 3.0 de-
pends on tau concentration. Various concen-
trations of 3.0 were incubated with four dif-
ferent concentrations of tau as indicated.
The degree of tau phosphorylation by Cdk5
was assayed by the filter method as de-
scribed in Experimental Procedures. The
ATP concentration was 400 M.
(H) Dixon Plot of the inhibitor 3.0. The recip-
rocal of Cdk5 activity derived from Figure 3A
was plotted against the concentration of in-
hibitor 3.0 at four different tau concentra-
tions as indicated. Data were analyzed with
GraphPad software. Each point represents
mean ± SEM.for GSK3β than Cdk5 and CDK1. It has low activity to-
ward other kinases. 3.0 has 2- to 3-fold greater inhibi-
tion toward Cdk5 compared with GSK3β and CDK1 and
showed only low activity toward the other kinases.
Cocrystallization of Compound 1.0 with cdk5/p25
To obtain structural information on the mode of binding
of 1.0 to Cdk5, we exploited well-diffracting trigonal
crystals of the Cdk5/p25 complex [39]. 1.0 was soaked
into the crystal, and diffraction data from a frozen crys-
tal were collected to a resolution of 2.1 Å (Supplemental
Table S2). The structure was determined using the Mo-
lecular Replacement technique (see Experimental Pro-
cedures). The structure confirms the kinetic result that
1.0 is an ATP competitor (Figure 3) and also provides
an excellent framework to understand the results of the
SAR analysis. 1.0 is sandwiched between the hy-
drophobic ceiling, walls, and floor of the Cdk5 ATP
binding site, containing, among others, the side chains
of Ile10, Val18, Ala31, Val64, Phe80, Phe82, Leu133, and
Ala143. Interestingly, 1.0 forms seven hydrogen bond
donor/acceptor interactions with the main chain and
side chain atoms of Cdk5, rather than the 3–4 often
observed for active site kinase inhibitors. Some of thebonds are suboptimal (see below), suggesting that the
compound can be improved to become an even more
effective Cdk5 ligand.
Interestingly, 1.0 induces a restructuring of the Gly-
rich loop of Cdk5. This occurs via the action of the hy-
droxyl group at R1, which is involved in two hydrogen
bonds with the main chain amide and carbonyl groups
of Glu12. We infer from the fact that there is excellent
electron density for the Gly-rich loop that these interac-
tions stabilize this loop, which is typically disordered in
crystal structures of Cdk5 and other kinases. We ob-
served a single water molecule in the active site of
Cdk5 bound to 1.0. The hydroxyl group at R2 is in prox-
imity to several potential hydrogen bond donors and
acceptors, including the amide group of Asp86 and the
carbonyl of Ile10. The distances and orientation of
these interactions, however, appear suboptimal, sug-
gesting that improved binding affinities may be achieved
by appropriate modification of the inhibitor. The hy-
droxyl group at R4 is within hydrogen bonding distance
with the carbonyl group of Glu81 (2.7 Å) and the main
chain amide of Cys83 (2.9 Å). These interactions ex-
plain why removal of the hydroxyl from this position
results in loss of activity. In other Cdk5-inhibitor com-
Chemistry & Biology
814Figure 2. Cell-Based Assays
(A) Effect of inhibitors on tau phosphorylation in cells. Three different concentrations of inhibitors were incubated in culture medium with
IMR-32 cells or primary neuron for 2 hr at 37°C. After incubation, cells were lysed and Western blot analysis were followed using PHF-1 or
total tau antibody. Upper blots are representative of three separate experiments and lower bar graph shows relative band intensity (mean ± SEM).
(B) Cytotoxicity test of inhibitors. Various concentrations (0.1–100 M) of inhibitors were applied into HT1080 cells and incubated for 24 or 48
hr. After incubation, cells were lysed and cell titer reagent (CellTiter 96 Aqueous One Solution Cell Proliferation Assay-Promega) were added
followed by incubation at 37°C for 2 hr. Color intensity was measured at 495 nm.plexes, including those with roscovitine, indirubin, aloi- f
asine [39], and 2.0 (see below), the carbonyl group of
Cys83 engages in a hydrogen bond with the inhibitor. t
mIn the complex with 1.0, no suitably placed groups in
the inhibitor can engage the carbonyl oxygen of Cys83. t
rFinally, the hydroxyl group at R5 is hydrogen bonded
with the side chain of Asn144, which replaces the cata- b
1lytic Asp144 in the inactive version of Cdk5 used for
crystallization. We expect that a similar interaction is i
hformed with Asp144, explaining why the removal of this
substituent decreases the potency of the compound. In m
dsummary, the structure points at the R1, R4, and R5
hydroxyl groups as being most critical for binding, in a
cagreement with the SAR analysis (see below).
s
lCocrystallization of Compound 2.0 with cdk5/p25
mWe also determined the 1.95 Å crystal structure of 2.0
tbound to the Cdk5/p25 complex using essentially the
Isame strategy described above (Figure 3). The electron
rdensity is usually significantly weaker for one of the two
CCdk5/p25 complexes present in the asymmetric unit of
ithe trigonal and well-diffracting crystal form of Cdk5/
lp25 used for these experiments, and we usually limit
wour analysis to the better defined of the two complexes.
hIn the particular case of 2.0, however, electron density
for the inhibitor was only observable in the active site
wof the less-defined Cdk5-p25 complex, while no density
was present in the other complex. This might reflect the iact that the penetration of the compound into the
ctive site of Cdk5 imposes a conformational change
hat is more easily sampled in the crystals by the more
obile (and therefore disordered) complex. At any rate,
he electron density of the inhibitor and of the sur-
ounding protein moiety was perfectly suited for unam-
iguous interpretation of the orientation of 2.0. As with
.0, we found that the inhibitor occupied the ATP bind-
ng pocket of the kinase. Like most ATP-site kinase in-
ibitors, 2.0 formed three hydrogen bonds with the
ain chain atoms of Glu81 and Cys83. A fourth hy-
rogen bond involved the nitrobenzene moiety of 2.0
nd engages the  amino group of Lys33. There is no
omparable ordering of the Gly-rich loop to that ob-
erved in the complex with 1.0. As a consequence, this
oop (residues 11–15) is partly disordered and was not
odeled. The interaction of 2.0 is partly reminiscent of
he mechanism of binding of roscovitine to Cdk5 [39].
n particular, the central 5-atom system and the 4-chlo-
oaniline ring of 2.0 are positioned in the active site of
dk5, like the 5-atom ring of purine and the benzylam-
ne substituent in roscovitine, respectively. No equiva-
ent of the interaction of the nitrobenzene group in 2.0
ith Lys33 is present in the roscovitine complex,
owever.
Modeling of the 2.0 cocrystal as an aligned overlay
ith four other Cdk5 inhibitor structures (1.0, aloisine-A,
ndirubin-3#-ozime, and (R)-roscovitine) revealed a sig-
Cdk5 Ligand Chemical Space
815Figure 3. Crystal Structure of 1.0 and 2.0 Bound to Cdk5/p25
(A and D) Ribbon model of Cdk5/p25 (light blue and gray) in complex with the inhibitor (space-filling model).
(B and E) Close-ups of the catalytic site of the kinase complexed with inhibitors. The residues of Cdk5 that contact the bound ligand are
depicted in ball-and-sticks, carbon atoms are in gray (protein) and tallow (inhibitor), oxygen atoms in red, and nitrogens in blue. Electron
density is shown in pink for the inhibitor only (contoured at 3 sigma level).
(C and F) Schematic drawing of the interaction between Cdk5 and inhibitors. Residues forming van der Waals interactions are indicated as
dashed moons, those engaged in hydrogen bonds are shown in ball-and-stick representation. Hydrogen bonds are depicted as dotted lines
with the donor-acceptor distance given in angstroms.
(G) Structural superposition of the active site of Cdk5 with the two ligands.nificant movement in two side chains (Asn144 and
Lys33) due to the 2.0 nitrophenyl group (Figure 4). Wild-
type Cdk5 has an aspartate in position 144, instead of
an asparagine in the inactive mutant. Therefore, Asn144
was computationally mutated to an aspartate (see Ex-
perimental Procedures). In the aligned mutated and
minimized structures, the position of Asp144 in the 2.0
structure is not as distinct from its positions in the other
structures, but the position of Lys33 is still unique (Fig-
ure 4). This observation fits well with the kinetic data
that 2.0 is a noncompetitive inhibitor of tau, and per-
haps this change in the side chain conformation plays
some role in the mode of tau inhibition.
Structure Activity Relationship of cdk5/p25 Inhibitor
Several derivatives of bellidin (compound 1) were as-
sayed for Cdk5/p25 inhibitory activity. Bellidifodin, 1.1,
a methylated derivative of bellidin, had comparable in-
hibitory activity with an IC50 = 0.7 M (Figure 1). This
example demonstrated that the hydroxyl group at the
3-position of the xanthen-9-one ring in bellidin was not
necessary for Cdk5/p25 inhibitory activity. However, the
natural product norsterigmatocystin, 1.2, was practi-cally devoid of Cdk5/p25 inhibitory activity with an
IC50 = 533 M. This example illustrated that the hy-
droxyl group at the 4-position of the xanthen-9-one in
bellidin was essential for Cdk5/p25 inhibitory activity.
The xanthen-9-one derivative 1.4, which lacks the hy-
droxyl group in the 8-position, had diminished activity
(IC50 = 26 M) compared to 1.0. However, when the
hydroxyl group is methylated as in 1.5, all Cdk5/p25
inhibitory activity was lost (IC50 > 1000 M).
These conclusions were supported by an X-ray
analysis of a cocrystal of Cdk5/p25 and bellidin. The
SAR results were analyzed through a comparison be-
tween actual and optimized ligand charge distributions.
The latter identifies and corrects points of electrostatic
noncomplementarity (Figure 5A). In the right panel, red
(blue) indicates atoms whose partial atomic charge is
more negative (positive) than optimal; atoms drawn
with larger radii have a more substantial effect on the
binding affinity than do those with smaller radii. Atoms
near group A have a small computed effect on affinity
due to their large solvent exposure, while those near
groups B and C have a large effect due to being buried
in the pocket. Many charge-sensitive regions of 1.0 are
Chemistry & Biology
816Figure 4. Displacement of Amino Acid Side
Chains by 2.0
(A) Aligned overlay of Cdk5 Asn144 and
Lys33 from five Cdk5/inhibitor structures
with 2.0. The amino acids from the Cdk5/2.0
structure, as well as 2.0, are shown in atom
colors, while amino acids from the other
structures are colored according to the leg-
end. Note the significant movement in these
two side chains due to the 2.0 nitrophenyl
group. Wild-type Cdk5 has an aspartate at
position 144 instead of an asparagine in the
kinase-dead mutant. As a check, Asn144
was computationally mutated to an aspartate.
(B) Aligned mutated and minimized struc-
tures (the minimization included both side
chains in the mobile region). Note that the
position of Asp144 in the 2.0 structure is not
as distinct from its positions in the other
structures, but the position of Lys33 is still
unique.already close to charge optimized, i.e., not many large t
(spheres are highly colored.
Several derivatives of 2.0 were also assayed for a
fCdk5/p25 inhibitory activity (Figure 1). Changing the
aryl ketone substituents was tolerated in the case of v
s2.1 (IC50 = 1.4 M). However, other aryl ketones, such
as 2.2 and 2.3, were detrimental to activity. Finally, re- 6
amoval of the amino group on the central thiazole ring
(i.e., 2.4) resulted in loss of all Cdk5/p25 kinase inhibi- i
itory activity. This observation was supported by the
Cdk5/p25 and 2.0 cocrystal structures that showed the
rparticipation of this amino group in an H-bond, and is
therefore expected to be critical for binding. s
(A similar charge-optimization analysis for 2.0 is
shown (Figure 5B). Atoms interacting with Cys83 and V
sGlu81 are near optimal, though there is room for im-
provement in the group that interacts with Glu81:O; the
nitrogen appears to be too negative. Interestingly, D
based on an alignment of Cdk5 with Cdk2/ATP com-
plex, 2.0 and ATP share two interactions—H bonds with T
residues 81 and 83—while 2.0 has a third interaction d
with the carbonyl of Cys83. f
k
cDefining the Chemical Space within
the Cdk5 ATP Pocket p
pRecently, the crystal structures of the active CDK5/p25
kinase complexed with three inhibitors (R)-roscovitine, i
paloisine-A, and indirubin-3#-oxime were reported [39].
These compounds are ATP-antagonists binding into the c
bwell-conserved catalytic pocket of the kinase with IC50
values in the range of 0.1–0.2 M. When these three B
gcompounds plus the two compounds presented here
are aligned, they all share overlapping chemical space w
p(Figure 6A). All five inhibitors interacted with the N-H
group of Cys83, four with the carbonyl group of Cys83, c
dand three with the carbonyl group of Glu81 (Figure 6A).
To look for common features among the five inhibitors, s
tthe actual partial atomic charge values of all five inhibi-ors were compared to their charge-optimized values
Figure 6B). The critical interactions with Cdk5, Glu81,
nd Cys83 as a whole seem to be well optimized in all
ive inhibitors. By fitting all of the inhibitors into their
an der Waals volume, it is apparent that in one dimen-
ion they share a relatively flat plane (Figures 6C and
D). The hydrophobic contacts are generally made
bove and below the flat binding pocket, while polar
nteractions are made along the flat dimension of the
nhibitors (Figure 6E).
When each of the five inhibitors was aligned inside a
epresentation of its corresponding Cdk5 ATP binding
ite, a potential pocket is present in all five structures
Figure 7). This pocket contacts Cdk5 residues Leu55,
al64, Phe80, Asn144, Phe145, and Ala143 and repre-
ents a potential space for rational drug design.
iscussion
he three compounds reported here inhibit Cdk5 by
istinct mechanisms and each suggests strategies for
uture inhibitor optimization. In the case of 1.0, both the
inetic and crystallographic data demonstrate that the
ompound binds competitively with ATP in the ATP
ocket. The highly conserved nature of this binding
ocket presents a challenge for the design of specific
nhibitor compounds. Comparisons with other com-
ounds that bind to the same site suggest that mole-
ules containing fused aromatic or heterocyclic rings
ind to the ATP site by fitting into the planar groove.
ased on an alignment of Cdk5 with Cdk2/ATP, this
roove is probably the site occupied by the adenine
hen ATP binds. The very strong skew toward com-
ounds with this planar configuration may be due to a
haracteristic of this binding pocket or limitations in the
iversity of the chemical library. However, portions of
ome inhibitors, such as the nitrophenyl ring of 2.0 or
he phenyl ring of roscovitine, extend uniquely into
Cdk5 Ligand Chemical Space
817Figure 5. Charge Optimization
(A) At left, the actual partial atomic charge
values of 1.0, as well as a schematic of hy-
drogen bonding interactions. At right, the
color on each atom represents the difference
between its actual partial atomic charge and
the charge-optimized value. A white atom in-
dicates that the atom’s current charge is
very close to the optimum. The radius of
each atom is proportional to the magnitude
of the diagonal element of the ligand desol-
vation matrix corresponding to that atom,
which correlates with the sensitivity of the
molecule’s binding energy to the charge on
that atom. A large atom in the figure, there-
fore, indicates that the molecule’s binding
energy is very sensitive to that atom’s
charge. As the charges on the surrounding
residues are critical to the electrostatic in-
teractions, the computationally mutated
N144D Cdk5 structures were used and the
surrounding residues were minimized along
with it.
Group R2: 1.0 was experimentally compared
to an analogous molecule where the O-H
group indicated by “R2” was methylated,
and the IC50 did not change considerably
(0.2–0.7 M). Note that this group is neither
well optimized nor in a location where the
binding energy is sensitive to its charges.
Group R4: 1.0 was experimentally compared
to an analog that lacked the O-H group indi-
cated by “R4,” and the IC50 became worse
by a factor of >1000 (0.2–532.7 M). Note
that this group is both well optimized and in
a location where the binding energy is sensi-
tive to its charges. Also, this group is in-
volved in making the interactions with Cys83
and Glu81 that have been highly conserved
in Cdk1, 2, 5, and 9 inhibitors, and other ki-
nase inhibitors.
Group R5: 1.0 was experimentally compared to an analog that lacked the O-H group indicated by “R5,” and the IC50 became considerably
worse (0.2–25.5 M), though not as strongly as the effect of deleting R4. This intermediate effect can be rationalized by noting that although
the binding free energy is expected to be quite sensitive to the charges on this group and the group itself is relatively well optimized, the
surrounding charges are not near optimal, as measured by the charges’ closeness to the corresponding charges on the charge-optimized
molecule.
Group R1: 1.0 was experimentally compared to an analog in which the −OH groups indicated by R1 and R2 were both methylated and the
IC50’s differ enormously (0.2 and >1000 M). The perturbation to R1 alone is expected to have a small effect electrostatically. The observed
effect is somewhat larger and may be due to cooperative effects with group R2, such as through an altered binding conformation/tautomer.
(B) Results from charge optimization on the 2.0 inhibitor are shown analogously to those in (A). Note that the charges on the atoms interacting
with Cys83 are nearly optimal, while the nitrogen atom in the NH2 interacting with Glu81 is too negative. Based on alignment with Cdk2/ATP
complex, ATP appears to make two H bonds with residues 81 and 83, while 2.0 has a third interaction with the carbonyl of Cys83. No such
interaction is seen for ATP. These three interactions are the same ones that ATP may make with Cdk5, based on an alignment of Cdk5 with
a Cdk2/ATP complex. An explanation of SAR data is not attempted based on charge optimization data because much of the SAR changes
were made on the nitro ring, which was very close to the unmodeled glycine-rich loop.areas of the ATP pocket not occupied by any of the
other.
2.0 is also a competitive inhibitor for ATP but a non-
competitive inhibitor for tau. As such, binding of the
compound to the ATP pocket affects tau binding. Non-
competitive inhibitors decrease maximum catalytic ac-
tivity (Vmax or Bmax) with minimal effect on substrate
binding affinity (Km or Kd). A possible basis for this ef-
fect may be apparent in the cocrystal, which revealed
a rotational movement of two side chains (Asn144 and
Lys33) due to the nitrophenyl group of 2.0. Interestingly,
none of the other compounds show this movement, nor
do the other inhibitors demonstrate this kinetic profile.
3.0 does not compete with ATP but does competewith tau at low tau concentrations. Given the complex-
ity of tau phosphorylation [44], inhibitors could be ex-
pected with unusual kinetic profiles. In this case, 3.0
may interfere with tau binding to the enzyme. The mod-
est specificity of the compound for Cdk5 supports this
possibility; however, more definitive data from at-
tempted cocrystallization failed to detect any density
corresponding to the inhibitor. However, Cdk5-p25
crystals soaked with 3.1, an active derivative of 3.0,
showed a rearrangement of the activation loop at posi-
tion Val163. The structure of Cdk5-p25 revealed a pecu-
liar orientation of the V162 carbonyl, very similar to
what was observed in fully active Cdk2-cyclinA phos-
phorylated on T160, despite the fact that the T-loop of
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818Figure 6. Comparison of Several CDK5 Inhibitors
(A) Aligned overlay of the five inhibitors. Inhibitor atoms that are involved in making hydrogen bonds to Glu81 or Cys83 are shown as spheres,
as are the relevant atoms in Glu81 and Cys83. Oxygen, nitrogen, hydrogen, and carbon atoms are colored red, blue, white, and cyan,
respectively. Note that all five inhibitors interact with the N-H group of Cys83, four with the carbonyl group of Cys83, and three with the
carbonyl group of Glu81.
(B) Aligned overlays of the five inhibitors. At left, the atoms are colored according to their partial atomic charges, and at right, they are colored
red (blue) if their charge is more negative (positive) than their optimal charges. The circled region shows the atoms that interact with Glu81
and Cys83 of Cdk5. Note that their charges are quite close to the corresponding charges in the charge-optimized molecules, and the binding
energies to Cdk5 are sensitive to the charges of these atoms. This analysis uses charge-optimization theory to highlight the importance of
satisfying these interactions. Computationally mutated N144D Cdk5 structures were used in all five charge optimizations.
(C) Aligned overlay of the five inhibitors in which the gold volume represents van der Waals volume that is common to all five inhibitors. Note
that the five inhibitors share a common plane.
(D) Different views of the union volume of the aligned five inhibitors, i.e., the volume occupied by at least one of the inhibitors. Note that the
shape is relatively flat in one dimension.
(E) Aligned overlay of the five inhibitors, colored according to the key above. The Cdk5-aligned residues shown are “critical contact residues,”
defined by having their solvent-accessible surface area change by at least 10 Å2 upon binding to each of the five inhibitors. The regions A,
B, and C denote the general locations of atoms involved in forming hydrogen bonds with Cys83 H, Cys83 O, and Glu81 O, respectively. Note
that the hydrophobic contacts are generally made above and below the flat binding pocket, while polar interactions are made along the flat
dimension of the inhibitors.Cdk5 is not phosphorylated [23]. The interpretation f
bgiven was that Cdk5 does not need to be phosphory-
lated on S159 and full activation is brought about by m
ethe mere binding of p25/p35. This fully active confor-
mation of the T-loop is unchanged in all the Cdk5-p25 s
structures observed with the other cocrystals (more
than ten structures). However, when soaked with 3.1, S
the T-loop assumed a different conformation, in which
the V162 carbonyl adopts an orientation resembling the C
cone observed in unphosphorylated Cdk2-cyclin A (and
hence not fully active). This conformation may explain w
mthe mechanism underlying the inhibition kinetics, par-
ticularly if the inhibitor is bound with a very low occu- A
spancy.
In conclusion, this report suggests strategies to dis- r
ecover specific Cdk5 small molecule inhibitors. Uniqueeatures of the Cdk5 ATP binding may permit selective
inding of ATP competitors. On the other hand, small
olecules that bind outside the Cdk5 ATP pocket, an
xample of which is suggested by compound 3.0, pre-
ent opportunities for selective inhibition.
ignificance
dk5 is an attractive target for a diverse set of medi-
al conditions that affect the nervous system and for
hich no treatments currently exist. Nearly all small
olecule inhibitors discovered to date compete with
TP and are likely to bind to the ATP pocket. The con-
ervation of the ATP binding pocket among Cdk5-
elated kinases represents a challenge to the discov-
ry of more selective compounds. We describe three
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819Figure 7. Binding Pocket Representations
Each of the five inhibitors aligned inside a
representation of its corresponding Cdk5
structure’s ATP binding site. The opening to
solvent is the bulge on the upper right of
each representation. The pink asterisks rep-
resent a potential pocket present in all five
structures into which one might rationally
design in the future work; this pocket con-
tacts CDK5 residues Leu55, Val64, Phe80,
Asn144, Phe145, and Ala143. (Note: for 2.0,
Aloisine-A, and indirubin-3#-oxime, there is
missing density in the crystal structure in a
small region above the inhibitors as viewed
in the figures, and as a result, the ATP bind-
ing site appears larger in this region than it
might actually be.)novel Cdk5 inhibitors, each with a distinct mode of
binding, and a computational analysis of how five dif-
ferent inhibitors fit into the Cdk5 binding pocket. One
compound pushes residues aside to make room for
the entry of a nitrophenyl group into the ATP pocket.
The SAR and charge optimization analysis maps out
the importance of filling and properly charging up dif-
ferent regions of the binding pocket. Results such as
the identification of a cavity within the ATP binding
pocket that was unfilled by all five inhibitors repre-
sents a direction for rationale design of novel com-
pounds. Finally, one the compounds offers the first
suggestion that small molecule inhibitors of Cdk5,
which are noncompetitive with ATP, might be discov-
erable.
Experimental Procedures
Preparation of Human Recombinant Tau
Tau was prepared according to the method previously described
[40]. Briefly, a plasmid with the longest human tau cDNA was trans-
formed into BL21 competent cells, following a procedure described
in Novagen’s pET system manual. After induction of the protein
expression using IPTG, cell pellets were collected and resus-
pended with MOPS buffer. The cell suspension was lysed by Micro-
fluidizer (Technika, Chester, CT). Taking advantage of the heat sta-
bility of tau [45], tau was placed in a boiling water bath for 10 min
and protein aggregates were removed by centrifugation. The re-
combinant tau was further purified by passing the diluted superna-
tant over a MonoS HiTrap column overnight. The protein concen-
tration was measured by the BCA method using bovine serum
albumin as the standard, and tau was stored at −80°C until used.
Synthesis of Compound Derivatives
See Supplemental Data.
In Vitro Kinase Assay of Tau Phosphorylation
Cdk5, 33P-ATP, and cofactors were added in the presence of tau
protein. The reaction mixture was incubated to allow Cdk5 to
transfer 33P from ATP to tau. After transferring the mixture to a
Durapore PVDF membrane (Millipore), trichloroacetic acid (Sigma)
was added to stop the reaction and precipitate proteins. The filters
were washed to remove the unreacted components. Then, the filter
was punched and the radioactivity of the precipitate bound on the
filter was counted. To test the inhibitory effects of the compounds,tau, histone H1, and a peptide derived from histone H1 (Pro-Lys-
Thr-Pro-Lys-Lys-Ala-Lys-Lys-Leu) were used as substrates to mea-
sure the Km for each substrate (data not shown).
Phosphorylation of Tau in ELISA Format
Concentrated Sulfo-NHS-LC-LC-Biotin (Pierce) was added to tau
(2 mg/ml) at a 20-fold molar excess. The reaction mixture was
placed on ice for 3 hr. Excess biotin reagent was removed by
Centricon (Millipore) in the presence of a large volume of phos-
phate-buffered saline. Biotinylated-tau was stored at −80°C until
use.
The assay conditions for phosphorylation of biotinylated tau
were similar to those described in the filter assay without the
[33P]ATP. The reaction was carried out for 60 min at 30°C and termi-
nated by addition of 10 l of 50 mM EDTA to a final concentration
of 10 mM. 40 l of the reaction mixture was transferred to a 384-
well plate coated with streptavidin (Greiner). The plate was incu-
bated at room temperature for an additional 1 hr to allow for cap-
ture of the biotinylated tau. The unbound tau was removed by six
washes with 120 l of PBST each. PHF-1 was used as a primary
antibody, and a rabbit anti-mouse antibody, which was conjugated
with horseradish peroxidase (Promega), was used as a reporter. 3,
3#,5,5#-Tetramethyl benzidine (TMB) was added as a substrate for
the peroxidase to develop the color product according to the man-
ufacturer’s instruction (PharMingen). The color was quantified
using a plate reader (SpectraMaxx 384, Molecular Devices) at 450
nm.
Kinetic Studies
Kinase assays were performed with various concentrations of ATP
or tau with cdk5/p25. The data were analyzed by a nonlinear least-
squares program to determine kinetic parameters using GraphPad
software.
Crystallography
Protein expression and purification were performed as previously
reported [23]. Crystallization of the complex was carried out by the
hanging-drop vapor diffusion technique using the streak-seeding
method for crystal optimization. Crystals were harvested into a sta-
bilizing solution of 13% (w/v) PEG 3350, 100 mM KI, 100 mM
bisTris-Propane (pH 7), and 10 mM DTT supplemented with 1 ml of
10 to 100 mM inhibitor molecule previously dissolved in DMSO.
Soaks were carried out for 48–72 hr, and crystals were subse-
quently cryoprotected by step-wise addition of stabilizing solution
plus 50% (w/v) glycerol up to a final concentration of 20% glycerol
before freezing in liquid nitrogen. Data were collected at beamlines
ID14-1 and ID14-2 of the European Synchrotron Radiation Facility
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820(ESRF) on an ADSC Q4R detector (λ = 0.933 Å). Data processing w
oand reduction were carried out with the HKL package [46]. Details
of the data collection and reduction are reported in Supplemental
Table S2. The structure was determined by molecular replacement
Cwith the atomic coordinates of the Cdk5-p25 complex (Protein Data
MBank code 1H4L) as the search model utilizing the program AMoRe
A[47]. After the first cycles of rigid-body refinement, difference Fou-
trier maps displayed clear electron densities in the active site for
cthe inhibitors. At this stage, a run of 15 cycles of ARP/wARP [48]
iwas performed to improve the density in the active site without
imodel bias. The resulting density was used to manually fit the in-
ahibitor models whose geometry was generated with the DRG pro-
tgram [49]. Subsequent refinement was pursued with alternating cy-
hcles of interactive model building and CNS [50] or REFMAC [51]
nprogram suites. Bulk solvent correction and anisotropic B factor
Hscaling were applied throughout the refinement procedures. To-
uward the end of the refinement, water molecule positions were
eadded using the water-pick routine included in CNS. TLS refine-
mment was implemented at the end of the refinement protocol to
lseparately model the anisotropic movement of the N- and C-ter-
tminal lobes of Cdk5 and of p25. The electron density map is signifi-
ucantly weaker for one of the two Cdk5-p25 complexes contained
Fin the a.s.u., and most of the analyses reported here rely on the
zbetter ordered one. The final model of the complex with compound
a1.0 consists of residues 1–292 for cdk5 and 145–293 for p25. Final
prefinement statistics are reported in Supplemental Table S2.
A
A
tCytotoxicity Test
wHT 1080 cells were prepared in clear Nunc 384-well tissue culture
oplate at 5000 cells per well in a 45 l volume. Various concentra-
vtions (0.1, 1, 10, and 100 M) of compounds were added and then
cincubated for 24 or 48 hr (one plate for each time point). 10 l of
tcell titre reagent (CellTiter 96 Aqueous One Solution Cell prolifera-
ttion Assay-Promega) was added to each well. After incubation,
Ccells were lysed with 2 l lysis buffer (9% triton) and incubated at
T37°C for 2 hr, and color density was measured at 495 nm.
t
i
sCell Culture and cdk5 Kinase Activity Assay in Cells
uInhibitors were incubated with human neuroblastoma IMR-32 cells
Cor primary neurons from rat brain for 2 hr at 37°C. We used IMR-
t32 cell line because it was reported that cdk5 is active in the cells
S[43]. The regulatory subunit of cdk5, p35 is constitutively expressed
Tin IMR-32 cells. The cell line was maintained under subconfluent
aconditions in EMEM medium (ATCC), supplemented with 0.5%
inonessential aminoacids, penicillin (100 U/ml), streptomycin (100
cg/ml), glutamine (2 mM), and 10% (v/v) fetal bovine serum in 75
dcm2 tissue culture flasks at 37°C in a humidified atmosphere with
C5% CO2. The growth medium was changed twice a week.
TCell extracts were obtained by lysing cells in lysis buffer (50 mM
mTris-HCl [pH 7.5], 250 mM NaCl, 5 mM EDTA [pH 8.0], 0.1% NP-40,
i5 mM DTT) supplemented with protease inhibitors (Roche) for 30
pmin at 4°C. Cell lysates were recovered and centrifuged at 10,000 ×
Ag for 5 min at 4°C. Protein concentration was determined by bi-
bcinchoninic acid (BCA) assay (Pierce).
t
p
AWestern Blot and Antibodies
Equal amounts of total protein were size fractionated by SDS-PAGE m
Å(10% Tris-Glycine gel, Invitrogen) and transferred to a nitrocellulose
membrane (Midwest Scientific). After blocking nonspecific binding t
wby incubation overnight at 4°C with phosphate-buffered saline
(GIBCO) containing 0.01% Tween 20 (PBST) and 5% nonfat milk, u
bmembranes were washed in PBST. For a determination of the level
of total and phosphorylated tau, membranes were incubated for 1 q
ahr at RT with rabbit polyclonal anti-human tau (1:1000) and PHF-1
antibody, respectively. After incubation with the secondary anti- m
sbody for 1 hr, membranes were washed with PBST. Then, mem-
branes were incubated with chemiluminescence dye (New England p
sBiolabs) for 1 min at room temperature and exposed to X-ray film
(Kodak).
cAnti-human tau antibody was purchased from Biosource (Cama-
rillo, CA). A phosphorylation-dependent anti-tau antibody (PHF-1) ias a generous gift from Dr. Peter Davies (Albert Einstein College
f Medicine, New York).
omputational Methods
olecular Models
ll crystal structures were systematically prepared for computa-
ional analysis using prepublication versions of the crystallographic
oordinates. The amide groups of Asn and Gln residues and the
midazole rings of His residues were flipped as necessary by exam-
ning the local side chain environments, and the tautomer/proton-
tion state of each histidine was also determined by visual inspec-
ion. Crystallographic water molecules that made fewer than two
ydrogen bond contacts with protein atoms within 3.5 Å were elimi-
ated, as well as those with a thermal B factor greater than 50. The
BUILD facility [52] in the CHARMM software package [53] was
sed to build all hydrogen atom positions. The CHARMm22 param-
ter set [54] was used for all protein atoms, with the TIP3P water
odel. Appropriate CHARMm22 atom types were assigned to each
igand molecule. Partial atomic charges for each ligand were ob-
ained from ab initio quantum mechanical calculations, by first
sing the GAUSSIAN98 package [55] with the restricted Hartree-
ock SCF approach and the 6-31G* basis set for geometry optimi-
ation starting from the ligand crystallographic coordinates. Then,
restrained fitting to the electrostatic potential (RESP) [56] was
erformed to determine the partial atomic charges [57].
lignment of Structures
lignment of all five CDK5/p25/inhibitor structures was done using
he MULTI facility in the program ProFit (Andrew C.R. Martin, http://
ww.bioinf.org.uk/software/profit/; [58]), which minimizes the rmsd
f a structure to the average of the other structures until con-
ergence is reached. The atoms involved in the alignment were α
arbons of residues within 5 Å of all five inhibitors in their respec-
ive structures. Using a 7 Å cutoff did not change the alignment no-
iceably.
ommon and Union Volumes
he intersection and union volumes of the five inhibitors were de-
ermined by laying a 0.25 Å cubic grid over the aligned overlay of
nhibitors and placing 1 Å radius spheres at grid points if the entire
phere was inside all five inhibitor volumes (for the common vol-
me) or at least one inhibitor’s volume (for the union volume).
HARMm22 vdW radii were used for the generation of the inhibi-
or volumes.
olvent-Accessible Surface Area Calculations
he critical contact residues were defined by having their solvent-
ccessible surface area (SASA) change by at least 10 Å2 upon bind-
ng. SASAs of the receptor residue atoms were calculated analyti-
ally using the CHARMM software package and CHARMm22 van
er Waals radii. A probe radius of 1.4 Å was used.
harge Optimization
he partial atomic charges of each ligand were adjusted to opti-
ize its binding affinity to Cdk5/p25 in continuum solvent accord-
ng to theory [59–61]. Because one goal in this study was to com-
are the optimization data with SAR results on kinase-active Cdk5,
sn144 in each crystal structure was computationally mutated
ack to wild-type aspartate. This was done in two ways to check
he robustness of the results. In the first method, the Asp was
laced in the exact conformation that had been occupied by the
sn. In the second method, Asp144 and all residues and water
olecules with a side chain heavy atom or polar hydrogen within 3
of side chain 144 were allowed to minimize. The rest of the pro-
ein, including the entire protein backbone, and the inhibitor and
ater molecules were kept fixed. Minimizations were carried out
sing the adapted-basis Newton-Raphson functionality (developed
y D.J. States; see [62]) in CHARMM. Methods 1 and 2 produced
ualitatively similar results. As a control, each inhibitor was also
llowed to minimize in separate runs, and in each case, the mini-
ized structure did not vary significantly from the unminimized
tructure, and results generated were qualitatively similar. In this
aper, all N144D results were obtained using method 2, where the
tructures have been minimized.
Matrix elements for the desolvation and interaction of ligand
harge centers upon binding to Cdk5/p25 were calculated by solv-
ng the linearized Poisson-Boltzmann equation with iterative finite-
Cdk5 Ligand Chemical Space
821difference methods using a locally modified version of the DELPHI
software package [63–65]. A 129 × 129 × 129 cubic grid was used,
corresponding to approximately 3.3 grid units/Å for these com-
plexes. A previously published focusing and translating procedure
was used [66]. The external dielectric constant was 80 and the pro-
tein dielectric constant was 4. PARSE radii [67] were used, and
hydrogens were included only on aromatic and polar groups. The
solvent probe radius used to determine the molecular surface was
1.4 Å and the Stern layer distance was set to 2.0 Å with a salt
concentration of 0.145 M. From solving the potentials in the bound
and unbound states by charging each ligand atom center to +1.0e,
ligand desolvation matrices and interaction vectors used in the
charge optimization process were assembled. The actual uncon-
strained charge optimizations were done using locally written soft-
ware [68]. Constrained optimizations were also performed using
the LOQO software package [69, 70], where the total charge was
constrained to be integral or where certain charges were held fixed.
ATP Binding Site Definition
The shapes of the ATP binding pocket in the various complexes
were defined using an iterative method that, at each iteration,
placed new spheres at user-defined points inside the pocket and
minimized the energy of all existing spheres while keeping protein
atoms fixed. During a minimization, only van der Waals (vdW) in-
teractions were included in the energy calculation, so that spheres
would move as close to protein and to each other as possible,
“filling up” the active site. Then, at the subsequent iteration, new
spheres were again placed at the same, fixed user-defined points
and the vdW energy was again minimized, allowing all spheres
present to move. Minimization was done with CHARMM, using
CHARMm22 parameters for the protein atoms. Water and inhibitors
were removed from the structure, leaving only protein. The vdW
well depth of a sphere-sphere interaction was set at 0.1 kcal/mol,
and the distance of maximal vdW interaction was fixed at 0.6 Å.
The optimal sphere-protein atom distance was set to (1.0 Å + the
vdW radius of the protein atom). 100 steps were taken at each
minimization. As the binding pockets for the various complexes
differed in size, the total number of iterations for each pocket was
chosen so that the entire binding pocket was full and spheres were
“spilling” out of the pocket. The radius of the spheres for visualiza-
tion purposes was 1.0 Å.
Visualization Software
All images were visualized using the program VMD [71]. Certain fig-
ures in this paper were generated using the Raster3D package [72].
Supplemental Data
Supplemental Data include two tables and Supplemental Experi-
mental Procedures and can be found with this article online at
http://www.chembiol.com/cgi/content/full/12/7/811/DC1/.
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